Moomoo AI 已提取核心訊息
On April 1, 2024, Donna Roy Grogan, associated with C4 Therapeutics, Inc. (ticker symbol: CCCC), completed a purchase transaction of the company's common stock. The transaction involved the acquisition of 1,697 shares at a price of $8.10 per share. Following this transaction, Grogan's direct holdings in C4 Therapeutics increased to a total of 23,632 shares. The transaction is reported to have been completed successfully, with no subsequent sales reported.
On April 1, 2024, Donna Roy Grogan, associated with C4 Therapeutics, Inc. (ticker symbol: CCCC), completed a purchase transaction of the company's common stock. The transaction involved the acquisition of 1,697 shares at a price of $8.10 per share. Following this transaction, Grogan's direct holdings in C4 Therapeutics increased to a total of 23,632 shares. The transaction is reported to have been completed successfully, with no subsequent sales reported.
2024年4月1日，與C4 Therapeutics, Inc.（股票代碼：CCCC）關聯的唐娜·羅伊·格羅根完成了該公司普通股的購買交易。該交易涉及以每股8.10美元的價格收購1,697股股票。在這筆交易之後，格羅根在C4 Therapeutics的直接持股量增加到總計23,632股。據報告，該交易已成功完成，隨後未報告任何銷售額。
2024年4月1日，與C4 Therapeutics, Inc.（股票代碼：CCCC）關聯的唐娜·羅伊·格羅根完成了該公司普通股的購買交易。該交易涉及以每股8.10美元的價格收購1,697股股票。在這筆交易之後，格羅根在C4 Therapeutics的直接持股量增加到總計23,632股。據報告，該交易已成功完成，隨後未報告任何銷售額。
有用
沒用